GLP-1 & Obesity

Apr 2, 2026

•

4 min read

Ozempic for Alzheimer’s?

Ozempic for Alzheimer’s? The EVOKE trials are in, and the answer is no. Novo Nordisk has terminated the programme and discontinued the planned one-year extension of both trials.

Cardio renal metabolic (CRM)

The first first large-scale comparative data: SGLT-2i vs. GLP-1 RA for kidney outcomes

Mar 11, 2026

•

12 min read

The first first large-scale comparative data: SGLT-2i vs. GLP-1 RA for kidney outcomes

PLUS: a year of NICE guideline changes, HRT evidence reviewed, and rare disease in UK primary care.

Prescribing Safety

MHRA Safety Update: Semaglutide and the Risk of Rare Vision Loss

Feb 22, 2026

•

3 min read

MHRA Safety Update: Semaglutide and the Risk of Rare Vision Loss

If you prescribe semaglutide, you need to know about this.

Cardio renal metabolic (CRM)

The Flozin-First Era, and 810,000 More GLP-1 Patients

Feb 22, 2026

•

5 min read

The Flozin-First Era, and 810,000 More GLP-1 Patients

NICE Rewrites the Type 2 Diabetes Script

Mental Health

Feature Article: The GLP-1 revolution, the good the bad and the ugly

Feb 5, 2026

•

5 min read

Feature Article: The GLP-1 revolution, the good the bad and the ugly

If it feels like your practice is increasingly dominated by patients asking for the "miracle jab," you aren’t alone.